Stratified cost‐effectiveness analysis: a framework for establishing efficient limited use criteria
- 14 February 2003
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 12 (5) , 421-427
- https://doi.org/10.1002/hec.788
Abstract
The cost-effectiveness of new health care technologies is conditional upon who receives what therapy and under what circumstances. Understanding this heterogeneity in cost-effectiveness, health care payers often limit reimbursement of therapies to a more restrictive sub-group of patients than that indicated in a product's licensing. Such limits may be based upon clinical or demographic criteria that are prognostic of costs, outcomes or both. However, there is little guidance on how to estimate and interpret stratified cost-effectiveness analysis. In this paper we present a framework for estimating the benefits from stratification that permits consideration of both the opportunity cost resulting from a lack of adherence with criteria and the efficiency loss associated with incorporating equity concerns. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- BAYESIAN VALUE-OF-INFORMATION ANALYSISInternational Journal of Technology Assessment in Health Care, 2001
- A Bayesian approach to sensitivity analysisHealth Economics, 1999
- Net Health BenefitsMedical Decision Making, 1998
- The measurement of individual utility and social welfareJournal of Health Economics, 1998
- Intergenerational Equity: An Exploration of the ‘Fair Innings’ ArgumentHealth Economics, 1997
- Health utility indices and equity considerationsJournal of Health Economics, 1997
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- The Problem of Discrimination in Health Care Priority SettingPublished by American Medical Association (AMA) ,1992